Xinzeyuan Medical Technology Co., Ltd, a minimally invasive surgical supply chain platform enterprise based in Hangzhou, has reportedly raised close to RMB 100 million (USD 13.7 million) via a Series B+ financing round. This significant capital injection will support the company’s ongoing efforts to expand its product portfolio and enhance its market presence in the minimally invasive surgical instruments sector.
Financing Details
The Series B+ round was led by new investors Shunbai Fund and Sanmei Investment, with participation from existing investor Qiming Venture Partners. The proceeds will be used to accelerate the development and commercialization of Xinzeyuan’s innovative products, further solidifying its position as a leading player in the minimally invasive surgical supply chain.
Company Background and Product Portfolio
Founded in 2015, Xinzeyuan has established a comprehensive product portfolio covering hard endoscopes, soft endoscopes, endoscopic surgical instruments, and minimally invasive surgical instruments. This diverse range of products positions Xinzeyuan to meet the evolving needs of healthcare providers and patients, driving innovation and efficiency in surgical procedures.-Fineline Info & Tech
